Siemens' PETNET Solutions, a wholly owned subsidiary of Siemens Healthcare, announced it will provide clinical researchers in the greater New York City area with access to gallium-68-labeled prostate-specific membrane antigen (Ga-68 labeled PSMA). This investigational tracer is being studied for prostate cancer imaging using positron emission tomography/computed tomography (PET/CT) in clinical trials throughout the world.
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now